Smith & Nephew PLC
Închisă
1,040.5 3.33
Rezumat
Modificarea prețului
24h
Minim
1007
Maxim
1014.5
Venit | -42M 301M |
|---|---|
Vânzări | -234M 3.1B |
P/E Medie Sector | 19.824 32.138 |
Randament dividend | 3.73 |
Marjă de profit | 9.784 |
Angajați | 17,000 |
EBITDA | -113M 773M |
Randament dividend Medie Sector | 3.73% 3.59% |
|---|---|
Data viitoare de dividende | 6 nov. 2026 |
Următoarea dată ex-dividende | 1 oct. 2026 |
Capitalizare de piață | -390M 9B |
|---|---|
Deschiderea anterioară | 1037.17 |
Închiderea anterioară | 1040.5 |
Smith & Nephew PLC Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Știri relevante
Comparație
Modificare preț
Smith & Nephew PLC Așteptări
Date financiare
Cheltuieli de vânzare și administrare
Cheltuieli de exploatare
Profit pre-impozitare
Vânzări
Costul vânzărilor
Profit brut din vânzări
Cheltuieli cu dobânzile pe datorie
EBITDA
Profit operațional
$
Despre Smith & Nephew PLC
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
